Significance of Circulating Tumor Cells in Patients With Squamous Cell Carcinoma of the Head and Neck

被引:106
|
作者
Jatana, Kris R. [1 ,3 ,4 ]
Balasubramanian, Priya [2 ]
Lang, Jas C. [1 ]
Yang, Liying [2 ]
Jatana, Courtney A.
White, Elisabeth [1 ]
Agrawal, Amit [1 ]
Ozer, Enver [1 ]
Schuller, David E. [1 ]
Teknos, Theodoros N. [1 ]
Chalmers, Jeffrey J. [2 ]
机构
[1] Ohio State Univ, Dept Otolaryngol Head & Neck Surg, Columbus, OH 43205 USA
[2] Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, Columbus, OH 43205 USA
[3] Ohio State Univ, Dept Oral & Maxillofacial Surg, Columbus, OH 43205 USA
[4] Nationwide Childrens Hosp, Columbus, OH 43205 USA
基金
美国国家科学基金会;
关键词
METASTATIC BREAST-CANCER; BONE-MARROW; PROGNOSTIC-SIGNIFICANCE; PERIPHERAL-BLOOD; LUNG-CANCER; ORAL TONGUE; SURVIVAL; PROGRESSION; ENRICHMENT; DISEASE;
D O I
10.1001/archoto.2010.223
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objectives: To present and discuss a high-performance negative depletion method for the isolation of circulating tumor cells (CTCs) in the blood of patients with head and neck cancer and to determine the correlation between the presence of CTCs and early clinical outcome in these patients. Design: Prospective clinical follow-up study of patients with squamous cell carcinoma of the head and neck (SCCHN) undergoing surgical intervention, who had peripheral blood examined for the presence of CTCs. Patients: The study population comprised 48 patients diagnosed as having SCCHN and undergoing surgical intervention. Intervention: A negative depletion process to isolate and quantify CTCs from the blood of patients with SCCHN using immunomagnetic separation was developed and validated. Immunostaining for cytokeratin was performed on the enriched samples to determine the number of CTCs extracted from each patient's blood sample. Correlation of the presence of CTCs, tumor stage, nodal status, clinical characteristics, and outcome was made. Main Outcome Measure: Disease-free survival. Results: Our initial data, that have a mean follow-up of 19.0 months, suggest that patients with no detectable CTCs per milliliter of blood had a significantly higher probability of disease-free survival (P=.01). There was no correlation between the presence of CTCs with regard to age, sex, tumor site, stage, or nodal involvement. Conclusions: Our enrichment technology, based on the removal of normal cells, has been used on the peripheral blood of patients with head and neck cancer for which follow-up data were collected. If no CTCs were present, a statistically significant improved disease-free survival was observed in SCCHN. A blood test with such a prognostic capability could have important implications in the treatment of patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2010;136(12):1274-1279
引用
收藏
页码:1274 / 1279
页数:6
相关论文
共 50 条
  • [41] Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer
    Hou, Jian-Mei
    Krebs, Matthew G.
    Lancashire, Lee
    Sloane, Robert
    Backen, Alison
    Swain, Rajeeb K.
    Priest, Lynsey J. C.
    Greystoke, Alastair
    Zhou, Cong
    Morris, Karen
    Ward, Tim
    Blackhall, Fiona H.
    Dive, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) : 525 - 532
  • [42] Clinical significance of circulating tumor cells in squamous cell lung cancer patients
    Qi, Yuanling
    Wang, Wenhui
    CANCER BIOMARKERS, 2017, 18 (02) : 161 - 167
  • [43] Therapeutic implications of tumor free margins in head and neck squamous cell carcinoma
    Backes, Clara
    Bier, Henning
    Knopf, Andreas
    ONCOTARGET, 2017, 8 (48) : 84320 - 84328
  • [44] Clinical significance of tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma
    Han, Lu
    Li, Yun-Jie
    Zhang, Wei-Di
    Song, Ping-Ping
    Li, Hao
    Li, Sheng
    MEDICINE, 2019, 98 (06)
  • [45] Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN)
    Galot, Rachel
    Machiels, Jean-Pascal H.
    CANCER TREATMENT REVIEWS, 2020, 85
  • [46] Prognostic impact and potential predictive role of baseline circulating tumor cells in locally advanced head and neck squamous cell carcinoma
    de Oliveira, Thiago Bueno
    Braun, Alexcia Camila
    Nicolau, Ulisses Ribaldo
    Abdallah, Emne Ali
    Alves, Vanessa da Silva
    Fonseca de Jesus, Victor Hugo
    Calsavara, Vinicius Fernando
    Kowaslki, Luiz Paulo
    Domingos Chinen, Ludmilla T.
    ORAL ONCOLOGY, 2021, 121
  • [47] The prognostic significance of estrogen receptor in head and neck squamous cell carcinoma
    Grsic, Kresimir
    Opacic, Iva Ledinsky
    Sitic, Sanda
    Perisa, Marija Milkovic
    Suton, Petar
    Sarcevic, Bozena
    ONCOLOGY LETTERS, 2016, 12 (05) : 3861 - 3865
  • [48] Genetic analysis of single disseminated tumor cells in the lymph nodes and bone marrow of patients with head and neck squamous cell carcinoma
    Sproll, Karl Christoph
    Schorn, Lara K.
    Reising, Benedikt
    Schumacher, Sarah
    Lommen, Julian
    Kuebler, Norbert R.
    Knoefel, Wolfram Trudo
    Beier, Manfred
    Neves, Rui P.
    Behrens, Bianca
    Horny, Kai
    Stoecklein, Nikolas H.
    MOLECULAR ONCOLOGY, 2022, 16 (02) : 333 - 346
  • [49] Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
    Califano, Joseph A.
    Khan, Zubair
    Noonan, Kimberly A.
    Rudraraju, Lakshmi
    Zhang, Zhe
    Wang, Hao
    Goodman, Steven
    Gourin, Christine G.
    Ha, Patrick K.
    Fakhry, Carole
    Saunders, John
    Levine, Marshall
    Tang, Mei
    Neuner, Geoffrey
    Richmon, Jeremy D.
    Blanco, Ray
    Agrawal, Nishant
    Koch, Wayne M.
    Marur, Shanthi
    Weed, Donald T.
    Serafini, Paolo
    Borrello, Ivan
    CLINICAL CANCER RESEARCH, 2015, 21 (01) : 30 - 38
  • [50] The effect of circulating tumor DNA on the prognosis of patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis
    Yang, Ruoyi
    Li, Teng
    Zhang, Sicheng
    Shui, Chunyan
    Ma, Hong
    Li, Chao
    BMC CANCER, 2024, 24 (01)